PROCEPT BioRobotics Corp

PROCEPT BioRobotics Corp. is a commercial-stage surgical robotics company, which engages in the development of transformative solutions in urology. It manufactures and sells the AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery, with an initial focus on treating BPH. The firm's proprietary AquaBeam Robotic System employs a single-use disposable handpiece to deliver its Aquablation therapy, which combines real-time, multidimensional imaging, personalized treatment planning, automated robotics and heat-free waterjet ablation for targeted and rapid removal of prostate tissue. The company was founded by Nikolai Aljuri and Rodney C. Perkins in 2007 and is headquartered in Redwood City, CA.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

PROCEPT BioRobotics Corp achieves record revenue growth, eyes market expansion

PROCEPT BioRobotics Corp demonstrated strong financial growth in Q4 2022, with revenue surging by 135% year-over-year, setting the stage for continued expansion and market success.
While facing challenges such as high operating expenses and margin pressures, the company remains focused on innovation, market diversification, and operational improvements to drive future profitability.
With a clear strategy to enhance sales efforts, expand market reach, and invest in R&D, PROCEPT BioRobotics Corp is well-positioned to capitalize on growth opportunities and solidify its presence in the medical technology sector.
Overall, the company's performance highlights a balance between revenue growth initiatives, cost management strategies, and a commitment to delivering high-quality healthcare solutions, signaling a positive outlook for future success.

PROCEPT BioRobotics Corp reports strong Q1 growth and eyes global expansion

PROCEPT BioRobotics Corp delivered strong Q1 results with robust revenue growth and margin expectations, despite profitability challenges.
The company's focus on long-term growth, pricing discipline, and market opportunities position it well for future success and becoming a standard of care for BPH.
While facing challenges like operating expenses and sales performance, PROCEPT BioRobotics remains optimistic about international expansion and market potential.
With a solid financial foundation, high surgeon retention rates, and exciting growth prospects in new markets, the company is poised for continued success.

PROCEPT BioRobotics Corp achieves record revenue and strategic partnerships

PROCEPT BioRobotics delivered a standout performance in Q2 2023, marked by record revenue, strong U.S. system sales, and international growth, supported by strategic partnerships and positive payer coverage updates.
While facing challenges from dilutive effects of new system placements and market evaluation complexities, the company's focus on innovation, financial strength, and growth opportunities position them well for future success.
By capitalizing on the momentum in system sales, expanding market reach, and leveraging the trend towards innovative treatments, PROCEPT BioRobotics is poised for continued growth and market leadership in the healthcare sector.

PROCEPT BioRobotics reports record Q3 revenue and eyes international expansion

PROCEPT BioRobotics delivered a strong quarter marked by revenue growth, improved gross margin, and strategic equity financing, positioning the company for future success.
While facing challenges in profitability and international sales, the company's focus on cost control, expansion, and innovative therapies presents avenues for growth and market leadership.
Overall, PRCT's performance reflects resilience and strategic foresight, supported by a confident management team and a clear vision for sustained growth and profitability.

PROCEPT BioRobotics Corp reports robust revenue growth and strategic focus

PROCEPT BioRobotics Corp delivered strong revenue growth in Q4 2023 and provided optimistic guidance for 2024, focusing on gross margin expansion and disciplined expense management.
The company's strategic strengths lie in innovation, customer base expansion, and patient awareness initiatives, while challenges include managing operating expenses and market dynamics.
Opportunities for PROCEPT include leveraging R&D investments, patient education, and market presentations to capture a larger share of the BPH patient population and drive utilization growth.
Overall, PROCEPT's performance highlights its commitment to long-term value creation, market stability, and strategic growth initiatives in the medical robotics sector.

PROCEPT BioRobotics Corp reports strong revenue growth and strategic advancements

PROCEPT BioRobotics Corp delivered strong revenue growth in Q1 2024, driven by robust U.S. sales and improved gross margins. The company's strategic focus on profitability, customer relationships, and product safety positions it well for future success.
While facing challenges with net losses and high operating expenses, PROCEPT BioRobotics Corp has opportunities to drive growth through ASC procedures, international expansion, and clinical trials. Leveraging strategic partnerships and market-leading products will be key to overcoming challenges and seizing opportunities.
Overall, PROCEPT BioRobotics Corp's Q1 performance reflects a mix of strengths, challenges, and opportunities. By navigating financial hurdles, capitalizing on market trends, and maintaining a customer-centric approach, the company can drive sustainable growth and enhance its competitive position.

PROCEPT BioRobotics reports strong revenue growth but faces profitability challenges

PROCEPT BioRobotics delivered robust revenue growth and margin expansion in Q2 2024, driven by strong U.S. sales and operational efficiency. However, escalating operating expenses led to a net loss and negative adjusted EBITDA.
The company's strategic focus on leveraging fixed costs and sustaining revenue growth presents opportunities for long-term profitability and market expansion. Balancing cost control with revenue generation will be crucial for future success.
Despite challenges in achieving profitability, PROCEPT BioRobotics remains confident in its ability to drive margin expansion through increased revenues and operational efficiencies, positioning itself for sustained growth and financial improvement.

PROCEPT BioRobotics excels in Q3 with revenue surge and innovation

PROCEPT BioRobotics delivered strong revenue growth, margin improvement, and operational progress in Q3 2024, underpinned by market acceptance and innovation.
While facing challenges in managing expenses and achieving profitability, the company's solid financial position and growth outlook offer opportunities for future success.
By focusing on cost optimization, product differentiation, and strategic investments, PROCEPT can navigate challenges and leverage opportunities to drive sustained growth and value creation.
Overall, PROCEPT's performance reflects resilience and potential for continued expansion in the robotic medical systems market, supported by a strong financial foundation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

PROCEPT BioRobotics Corp. is a commercial-stage surgical robotics company, which engages in the development of transformative solutions in urology. It manufactures and sells the AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery, with an initial focus on treating BPH. The firm's proprietary AquaBeam Robotic System employs a single-use disposable handpiece to deliver its Aquablation therapy, which combines real-time, multidimensional imaging, personalized treatment planning, automated robotics and heat-free waterjet ablation for targeted and rapid removal of prostate tissue. The company was founded by Nikolai Aljuri and Rodney C. Perkins in 2007 and is headquartered in San Jose, CA.

Viking Global leader Andreas Halvorsen (Trades, Portfolio) disclosed earlier this week he curbed his PROCEPT BioRobotics Corp. ( PRCT , Financial) stake by 25.45%.

Andreas Halvorsen Powers Down Position in PROCEPT BioRobotics

PROCEPT BioRobotics (PRCT) CEO Reza Zadno on Q4 2021 Results - Earnings Call Transcript

REDWOOD CITY, Calif., March 08, 2022 (GLOBE NEWSWIRE) -- PROCEPT® BioRobotics (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported financial results for the fourth quarter and full year ended December 31, 2021.

PROCEPT BioRobotics Reports Fourth Quarter and Full Year 2021 Financial Results

Procept BioRobotics Corp (NASDAQ: PRCT) announced five-year results from the WATER study comparing Aquablation therapy to TURP, the historical standard of care for treating benign prostatic hyperplasia (BPH). Procept is a surgical robotics company that develops, manufactures, and sells the AquaBeam Robotic Surgical System for minimally-invasive urologic surgery with an initial focus on treating BPH.

Procept BioRobotics' Aquablation Therapy Shows Encouraging Five-Year Data In Prostate Gland Enlargement

– Symptom reduction and uroflow improvement proved durable and consistent compared to TURP

PROCEPT Announces 5-Year WATER Study Data Comparing Aquablation to TURP

4D Molecular Therapeutics

First Watch Restaurant Group

NerdWallet

Singular Genomics Systems

VectivBio Holding AG

The U.S. IPO market was red-hot in 2021. The total number of traditional U.S. IPOs hit its highest level since the dot-com boom in the late 1990s, while total IPO deal value reached record levels last year.

6 Underperforming IPO Stocks To Buy On The Dip

REDWOOD CITY, Calif., Feb. 01, 2022 (GLOBE NEWSWIRE) -- PROCEPT® BioRobotics Corporation (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced that members of management will present virtually at the following two investor conferences:

PROCEPT BioRobotics Corp. to Present at 11th Annual SVB Leerink Global Healthcare Conference and Cowen's 42nd Annual Health Care Conference

First and only image-guided, heat-free surgical robotic procedure aims to establish a new standard of care for patients with enlarged prostates First and only image-guided, heat-free surgical robotic procedure aims to establish a new standard of care for patients with enlarged prostates

Northside Healthcare System in Atlanta Advances Surgical Robotics Program with Multi-System, Multi-Hospital Agreement for PROCEPT BioRobotics AquaBeam Systems

REDWOOD CITY, Calif., Jan. 11, 2022 (GLOBE NEWSWIRE) -- PROCEPT® BioRobotics Corporation (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported preliminary unaudited revenue for the fourth quarter and fiscal year ended December 31, 2021.

PROCEPT BioRobotics Corp. Announces Preliminary Fourth Quarter and Fiscal Year 2021 Revenue

REDWOOD CITY, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- PROCEPT® BioRobotics Corporation (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced the appointment of Mary Garrett to its Board of Directors.

PROCEPT BioRobotics Appoints Mary Garrett to Board of Directors

PROCEPT BioRobotics' (PRCT) CEO Reza Zadno on Q3 2021 Results - Earnings Call Transcript

REDWOOD CITY, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) --  PROCEPT® BioRobotics Corporation (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported financial results for the quarter ended September 30, 2021.

PROCEPT BioRobotics Corp. Reports Third Quarter 2021 Financial Results and Provides 2021 Revenue Guidance

REDWOOD CITY, Calif., Oct. 26, 2021 (GLOBE NEWSWIRE) -- PROCEPT® BioRobotics Corporation (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced the appointment of Elisabeth Sandoval to its Board of Directors.

PROCEPT BioRobotics Appoints Elisabeth Sandoval to Board of Directors

REDWOOD CITY, Calif., Oct. 21, 2021 (GLOBE NEWSWIRE) -- PROCEPT® BioRobotics Corporation (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the third quarter 2021 after the market close on Thursday, November 4, 2021. The company's management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

PROCEPT BioRobotics Corp. to Report Third Quarter 2021 Financial Results on November 4, 2021

REDWOOD CITY, Calif., Sept. 28, 2021 (GLOBE NEWSWIRE) -- PROCEPT® BioRobotics Corporation (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced a new positive coverage decision from Cigna, expanding access to Aquablation therapy for the treatment of their members with Benign Prostatic Hyperplasia. The revised policy is effective September 15, 2021.

PROCEPT BioRobotics Corporation Announces Cigna Adds Aquablation Therapy to its Coverage Policy

Viking Global leader Andreas Halvorsen (Trades, Portfolio) disclosed a position in PROCEPT BioRobotics Corp. ( PRCT , Financial) earlier this week, seeing a value opportunity in a newly public company.

Andreas Halvorsen Assembles Position in PROCEPT BioRobotics

REDWOOD CITY, Calif., Sept. 21, 2021 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (Nasdaq: PRCT) (“PROCEPT”), a commercial-stage surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced the closing of its upsized initial public offering of 7,539,400 shares of its common stock, including the full exercise of the underwriters' option to purchase up to 983,400 additional shares of common stock, at a public offering price of $25.00 per share. All of the shares were offered by PROCEPT. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses, were approximately $188.5 million. The shares began trading on the Nasdaq Global Market on September 15, 2021 under the ticker symbol "PRCT."

PROCEPT BioRobotics Corporation Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

Enact Holdings

Dutch Bros

EzFill Holdings

ForgeRock

On Holding AG

Rose Hill Acquisition Corp

Sportradar Group AG

Wetouch Technology Inc

The IPO market was full steam ahead this past week as 11 IPOs came to market.

U.S. IPO Weekly Recap: The Fall IPO Market Is In Full Swing With An 11 IPO Week

Procept BioRobotics Corp. PRCT, +45.96% debuted on Wall Street Wednesday with a bang, as the California-based surgical robotics company's stock opened 40.0% above the up-sized initial public offering's price. The company had said overnight that it raised $163.9 million as it sold 6.56 million shares in the IPO, which priced at $25.00, compared with previous expectations of a 5.5 million-share offering at an expected price of between $22 and $24 a share.

Procept BioRobotics stock debuts with a bang, as stock opens 40% above IPO price

Procept BioRobotics Corp. PRCT, is set to go public Wednesday, as the California-based surgical robotics company's upsized initial public offering priced above the expected range at $25.00 per share. The company sold 6.56 million shares in the IPO to raise $163.9 million.

Procept BioRobotics upsized IPO prices above the expected range, valuing company at $1 billion

REDWOOD CITY, Calif., Sept. 14, 2021 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (Nasdaq: PRCT) (“PROCEPT”), a commercial-stage surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced the pricing of its upsized initial public offering of 6,556,000 shares of its common stock at a public offering price of $25.00 per share, for total gross proceeds of $163.9 million, before deducting underwriting discounts and commissions and estimated offering expenses. All of the shares are being offered and sold by PROCEPT. PROCEPT's common stock is expected to begin trading on the Nasdaq Global Market on September 15, 2021, under the ticker symbol "PRCT." The offering is expected to close on September 17, 2021, subject to the satisfaction of customary closing conditions. In addition, PROCEPT has granted the underwriters a 30-day option to purchase up to an additional 983,400 shares of common stock at the initial public offering price, less the underwriting discounts and commissions.

PROCEPT BioRobotics Corporation Announces Pricing of Upsized Initial Public Offering

With the start of a new week comes the excitement surrounding a new set of companies looking to make an impact through their public offerings. According to Benzinga Pro, these enticing companies are scheduled to trade publicly this week.

News for PROCEPT BioRobotics Corp Stock (PRCT)